Clinical use of Infliximab in Crohn's disease: The Edinburgh experience

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 10, 2001, Pages 1639-1646

  Arnott, I D R ^a,c   McDonald, D ^b   Williams, A ^b   Ghosh, S ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b ST JOHN'S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIBODY; AZATHIOPRINE; CHLORPHENIRAMINE; COMPLEMENT; DOUBLE STRANDED DNA; HYDROCORTISONE; INFLIXIMAB; MESALAZINE; METHOTREXATE; PREDNISOLONE;

ADOLESCENT; ADULT; AGED; ANAPHYLAXIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DRUG COST; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; MALE; NAUSEA; PATIENT SELECTION; PERIANAL ABSCESS; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT INDICATION;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; CELIAC DISEASE; COHORT STUDIES; CROHN DISEASE; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL FISTULA; MALE; MIDDLE AGED; POUCHITIS; PROGNOSIS; PROSPECTIVE STUDIES; PYODERMA GANGRENOSUM; STEROIDS; TREATMENT OUTCOME;

EID: 0034798812     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.01092.x     Document Type: Article

References (27)

1. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
2. Infliximab for the treatment of fistulas in patients with Crohn's disease
3. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
4. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
5. Infliximab in Crohn's disease: First anniversary clinical experience
6. Clinical experience with infliximab therapy in 100 patients with Crohn's disease
7. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: The first 100 patients
8. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
9. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
10. Twenty cases of peristomal pyoderma gangrenosum: Diagnostic implications and management
11. Successful management of Crohn's disease of the ileoanal pouch with infliximab
12. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab
13. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions
14. A simple index of Crohn's disease activity
15. Crohn's disease: Concordance for site and clinical type in affected family members - Potential hereditary influences
16. Administration of infliximab in Crohn's disease does not deplete complement components C3 and C4
17. Use of anti-tumour necrosis factor agents in inflammatory bowel disease - European guidelines for 2001-2003
18. Assessment of disease activity in ulcerative colitis and Crohn's disease
19. Development of a Crohn's disease index: National cooperative Crohn's disease study
20. Anal lesions: Any significant prognosis in Crohn's disease?
21. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study
22. Cytokine production in pouchitis is similar to that in ulcerative colitis
23. The pathogenesis of celiac disease
24. Intestinal crypt ceil apoptosis in murine acute graft versus host disease is mediated by tumour necrosis factor alpha and not by the FasL-Fas interaction: Effect of pentoxifylline on the development of mucosal atrophy
25. Increased small intestinal apoptosis in coeliac disease
26. Severe anaphylactic reaction to infliximab: Report of a case
27. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)